Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC).

Justin F.  Gainor

Honoraria - ARIAD; Incyte; Merck; Novartis; Pfizer; Takeda

Consulting or Advisory Role - Agios; Amgen; Array BioPharma; Bristol-Myers Squibb; Genentech; Jounce Therapeutics; Loxo; Merck; Oncorus; Regeneron; Takeda; Theravance

Research Funding - Adaptimmune (Inst); Alexo Therapeutics (Inst); ARIAD; Array BioPharma (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Genentech; Jounce Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Tesaro (Inst)

Dae Ho  Lee

Honoraria - Abbvie; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Chong Kun Dang Pharmaceutical; CJ Healthcare; Janssen; Lilly; Merck; MSD; Mundipharma; Novartis; Ono Pharmaceutical; Pfizer; Roche/Genentech; Samyang; ST Cube; Takeda

Consulting or Advisory Role - ST Cube

Giuseppe  Curigliano

Honoraria - Ellipses Pharma

Consulting or Advisory Role - Bristol-Myers Squibb; Foundation Medicine; Lilly; Novartis; Pfizer; Roche/Genentech; Samsung

Speakers' Bureau - Foundation Medicine; Lilly; Novartis; Pfizer; Roche/Genentech; Samsung

Travel, Accommodations, Expenses - Pfizer; Roche/Genentech

Robert Charles  Doebele

Stock and Other Ownership Interests  - Rain Therapeutics

Consulting or Advisory Role - AstraZeneca; Bayer; GreenPeptide; Ignyta; OncoMed; Rain Therapeutics; Roche/Genentech; Takeda

Research Funding - Ignyta (Inst)

Patents, Royalties, Other Intellectual Property - Licensing fees for biologic materials from Genentech (Inst); Licensing fees for patent from Rain Therapeutics; Licensing Fees from Abbott Molecular for Patent PCT/US2013/057495; Licensing fees from Ignyta for biologic materials (Inst)

Travel, Accommodations, Expenses - Ignyta; Rain Therapeutics; Roche/Genentech

Dong-Wan  Kim

Research Funding - Alpha Biopharma (Inst); AstraZeneca/MedImmune (Inst); Hanmi (Inst); Janssen (Inst); Merus (Inst); Mirati Therapeutics (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst); TP Therapeutics (Inst); Xcovery (Inst); Yuhan (Inst)

Christina S  Baik

Consulting or Advisory Role - AstraZeneca; Novartis

Research Funding - AstraZeneca (Inst); Celgene (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Loxo (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst)

Daniel Shao-Weng  Tan

Honoraria - Bristol-Myers Squibb; Novartis; Pfizer; Roche; Takeda

Consulting or Advisory Role - AstraZeneca; Loxo; Merck; Novartis; Pfizer; Roche

Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Novartis (Inst)

Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer; Roche

Gilberto  Lopes

Consulting or Advisory Role - Pfizer

Research Funding - AstraZeneca; AstraZeneca (Inst); Bavarian Nordic (Inst); Blueprint Medicines (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Merck Sharp & Dohme (Inst); NOVARTIS (Inst); Tesaro (Inst)

Shirish M.  Gadgeel

Honoraria - AstraZeneca; Genentech/Roche

Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Pfizer; Takeda

Research Funding - Aeglea Biotherapeutics (Inst); ARIAD/Takeda (Inst); Astellas Pharma (Inst); Blueprint Medicines (Inst); Daiichi Sankyo (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Lycera (Inst); Merck; Merck (Inst); Pfizer (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche

Philippe Alexandre  Cassier

Honoraria - Amgen; Blueprint Medicines; Novartis; Roche/Genentech

Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Innate Pharma (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst); Transgene (Inst)

Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Merck Sharp & Dohme; Novartis; Roche

Matthew H.  Taylor

Consulting or Advisory Role - ArQule; Array BioPharma; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Eisai; Loxo; Novartis

Speakers' Bureau - Bristol-Myers Squibb; Eisai

Stephen V.  Liu

Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Celgene; Genentech; HERON; Lilly; Pfizer; Regeneron; Taiho Pharmaceutical; Takeda

Research Funding - AstraZeneca; Bayer; Blueprint Medicines; Clovis Oncology; Corvus Pharmaceuticals; Esanex; Genentech/Roche; Lilly; Lycera; Merck; Molecular Partners; OncoMed; Pfizer; Threshold Pharmaceuticals

Benjamin  Besse

Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Biogen (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Inivata (Inst); Ipsen (Inst); Lilly (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Nektar (Inst); Onxeo (Inst); Pfizer (Inst); PharmaMar (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst); Tiziana Therapeutics (Inst)

Michael  Thomas

Honoraria - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Lilly; MSD; Novartis; Pfizer; Roche; Takeda

Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; IQvia; IQvia; Lilly; Mediolanum Farmaceutici; MSD; Novartis; Pfizer; Roche; Takeda

Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Roche (Inst); Takeda (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; MSD; Novartis; Pfizer; Roche; Takeda

Viola Weijia  Zhu

Stock and Other Ownership Interests  - TP Therapeutics (I)

Honoraria - AstraZeneca; Roche/Foundation Medicine; Roche/Genentech; Takeda

Consulting or Advisory Role - TP Therapeutics

Speakers' Bureau - AstraZeneca; Roche/Foundation Medicine; Roche/Genentech; Takeda

Hui  Zhang

Employment - Blueprint Medicines

Stock and Other Ownership Interests  - Blueprint Medicines

Corinne  Clifford

Employment - Blueprint Medicines

Stock and Other Ownership Interests  - Blueprint Medicines

Michael  Palmer

No Relationships to Disclose

Christopher D.  Turner

Employment - Blueprint Medicines; Celldex

Stock and Other Ownership Interests  - Blueprint Medicines; Celldex

Vivek  Subbiah

Consulting or Advisory Role - MedImmune

Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Takeda (Inst); Vegenics (Inst)

Travel, Accommodations, Expenses - Bayer; PharmaMar